A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2009
12/17/2009	WO2009152082A1 Hydroxyphenylsulfonamides as antiapoptotic bcl inhibitors
12/17/2009	WO2009152079A1 Melanocortin receptor-specific peptides for treatment of sexual dysfunction
12/17/2009	WO2009152072A1 Pyrrolo [2, 3-c] pyridine derivatives as p38 kinase inhibiting agents
12/17/2009	WO2009152071A1 Unnatural dispyrin analogues, preparation and uses thereof
12/17/2009	WO2009152053A1 Methods of treating alpha adrenergic mediated conditions using imidazoline derivates
12/17/2009	WO2009152052A1 Methods of treating alpha adrenergic mediated conditions
12/17/2009	WO2009152041A2 Controlled release formulations of pramipexole
12/17/2009	WO2009152027A1 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
12/17/2009	WO2009151997A1 Process for producing bicycloaniline derivatives
12/17/2009	WO2009151991A1 Pyrazole derivatives useful as inhibitors of faah
12/17/2009	WO2009151974A1 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
12/17/2009	WO2009151972A1 Small molecule inhibitors of botulinum neurotoxins
12/17/2009	WO2009151920A2 Hepsin inhibitors
12/17/2009	WO2009151914A1 Methods for treating neoplasms with a combination of a plk inhibitor and retinoid
12/17/2009	WO2009151910A2 Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
12/17/2009	WO2009151845A1 Compounds for rho kinase inhibition and for improving learning and memory
12/17/2009	WO2009151770A2 Colchicine solid-state forms; methods of making; and methods of use thereof
12/17/2009	WO2009151762A2 Anticancer methods using extracts of anemarrhena asphodeloides bunge
12/17/2009	WO2009151742A2 Methods for identifying nuclear receptor/ligand combinations for targeting brain tumor stem cells for their use
12/17/2009	WO2009151741A1 Methods and compositions for the intracerebroventricular administration of felbamate
12/17/2009	WO2009151712A2 Substituted phenylcyclohexylglycolates
12/17/2009	WO2009151691A2 Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof
12/17/2009	WO2009151683A2 Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
12/17/2009	WO2009151646A2 Non-invasive diagnostic agents and methods of diagnosing infectious disease
12/17/2009	WO2009151644A2 Small molecule inhibitors of autotaxin methods of use
12/17/2009	WO2009151626A1 Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
12/17/2009	WO2009151625A1 Rasagiline for parkinson's disease modification
12/17/2009	WO2009151621A1 Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
12/17/2009	WO2009151620A2 Pain treatment using erk2 inhibitors
12/17/2009	WO2009151619A1 Povidone iodine, a novel alternative preservative for ophthalmic compositions
12/17/2009	WO2009151613A1 Oxybutynin derivatives
12/17/2009	WO2009151599A1 Substituted pyrroles and methods of use
12/17/2009	WO2009151598A1 Diazacarbazoles and methods of use
12/17/2009	WO2009151594A1 Rasagiline soft gelatin capsules
12/17/2009	WO2009151589A1 Diazacarbazoles and methods of use
12/17/2009	WO2009151569A2 Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
12/17/2009	WO2009151561A2 Methods and compounds for antimicrobial intervention
12/17/2009	WO2009151539A1 COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
12/17/2009	WO2009151529A1 Novel modulators of sphingosine phosphate receptors
12/17/2009	WO2009151498A2 Memantine formulations
12/17/2009	WO2009151496A2 Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
12/17/2009	WO2009151457A1 Nutritional preparations
12/17/2009	WO2009151456A1 Thiazole compounds, and compositions and methods using same
12/17/2009	WO2009151394A1 Sublingual compositions comprising (2s) - (4e) -n-methyl-5- (3- (5-isopropoxypyridin) yl) -4-penten-2-amine
12/17/2009	WO2009151393A1 Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
12/17/2009	WO2009151392A1 Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
12/17/2009	WO2009151331A1 Immune system stimulating nutrition
12/17/2009	WO2009151330A1 Nutritional composition for infants delivered via caesarean section
12/17/2009	WO2009151329A1 Nutrition for prevention of infections
12/17/2009	WO2009151315A1 Nutritional composition for infants delivered via caesarean section
12/17/2009	WO2009151152A1 Oxycarbamoyl compounds and the use thereof
12/17/2009	WO2009151125A1 Diagnosis and treatment of hepatic disorder
12/17/2009	WO2009151116A1 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
12/17/2009	WO2009151098A1 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
12/17/2009	WO2009151094A1 HUMAN β3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME
12/17/2009	WO2009151072A1 Tablet quickly disintegrating in the oral cavity and method for producing the same
12/17/2009	WO2009151069A1 Imidazothiazole derivative having 4,7-diazaspiro[2.5]octane ring structure
12/17/2009	WO2009151057A1 Process for production of antioxidant active substance
12/17/2009	WO2009151035A1 Therapeutic agent for overactive bladder
12/17/2009	WO2009151016A1 Method for producing 1-biphenylmethylimidazole compound
12/17/2009	WO2009150902A1 Composition for external use
12/17/2009	WO2009150753A1 Blood coagulation reaction inhibitor
12/17/2009	WO2009150668A1 Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
12/17/2009	WO2009150665A1 Orally disintegrating pharmaceutical compositions of escitalopram and salts thereof
12/17/2009	WO2009150630A2 Process for preparing a carbapenem antibiotic composition
12/17/2009	WO2009150535A1 Dronedarone for the prevention of permanent atrial fibrillation
12/17/2009	WO2009150534A1 Dronedarone for the prevention of cardioversion
12/17/2009	WO2009150530A2 Novel foam composition
12/17/2009	WO2009150524A1 Process for preparing a benzoylbenzeneacetamide derivative
12/17/2009	WO2009150474A1 Dihydrotetrabenanzine for the treatment of anxiety
12/17/2009	WO2009150462A1 Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
12/17/2009	WO2009150430A2 Vaccine
12/17/2009	WO2009150420A2 Inhibitors
12/17/2009	WO2009150408A2 Topical antimuscarinic formulations
12/17/2009	WO2009150405A1 Combination of spacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine
12/17/2009	WO2009150388A1 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
12/17/2009	WO2009150387A1 Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
12/17/2009	WO2009150381A2 Azacarboline derivatives, preparation method thereof and therapeutic use of same
12/17/2009	WO2009150344A1 Novel nucleic acid transfer system
12/17/2009	WO2009150331A1 Novel azabicyclic derivatives, preparation method for same, and pharmaceutical compositions containing same
12/17/2009	WO2009150318A1 Novel 2-substituted quinoline derivatives, and method for preparing same
12/17/2009	WO2009150281A1 Use of lauryl gallate in the prevention and treatment of infections caused by african swine fever virus (asfv)
12/17/2009	WO2009150257A2 Compositions for treating rosacea
12/17/2009	WO2009150248A1 Compounds which can be used for the treatment of cancers
12/17/2009	WO2009150240A1 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
12/17/2009	WO2009150230A1 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
12/17/2009	WO2009150196A1 N-thiazolyl-1, 2, 3, 4-tetrahydro-6-isoquinolinecarboxamide derivatives as inhibitors of stearoyl coenzyme a desaturase
12/17/2009	WO2009150194A1 Telaprevir dosing regimen
12/17/2009	WO2009150179A2 Plant extract and pufa combinations
12/17/2009	WO2009150144A1 New gpr119modulators
12/17/2009	WO2009150141A1 Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators
12/17/2009	WO2009150138A1 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use
12/17/2009	WO2009150137A2 Organic compounds
12/17/2009	WO2009150136A1 Novel embedment particles for inhalation
12/17/2009	WO2009150129A1 Heterocyclic derivatives as hdac inhibitors
12/17/2009	WO2009150119A1 Novel polymorphic forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
12/17/2009	WO2009150118A2 Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
12/17/2009	WO2009150110A1 Pyrrolidine ether derivatives as nk3 receptor antagonists
12/17/2009	WO2009150109A1 Imidazolidine derivatives
12/17/2009	WO2009150101A1 Pharmaceutical compositions comprising n-[2-((2r)-2-{[4-[(4-chlorophenyl)methyl]-l-oxo-2(ih)-phthalaz inyl]methyl}-l- pyrrolidinyl)ethyl]-4-(methyloxy)butanamide

1 ... 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 ... 7860